Amedisys (AMED) Tops Q2 EPS by 53c, Revs Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Amedisys Reports Second Quarter 2020 Financial Results - Reissues 2020 Guidance
July 28, 2020 4:05 PM EDTBATON ROUGE, La., July 28, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month period ended June 30, 2020.
Three-Month Periods Ended June 30, 2020 and 2019
Net service revenue decreased $8.0Â million to $485.0Â million compared to $493.0Â million in 2019.Net income attributable to Amedisys, Inc. of $34.7Â million compared to $33.7Â million in 2019.Net income attributable to Amedisys, Inc. per diluted share of $1.04 compared to $1.02 in 2019.Adjusted Quarterly Results*
Adjusted EBITDA of $66.4Â million compared to $61.4Â million in 2019.Adjusted net service revenue of $485.0Â million compared to $498.5Â million in... More